A recently approved twice-yearly injection to prevent HIV may warrant a higher price, but thousands of dollars more? CVS Caremark’s chief medical officer calls on Gilead Sciences to lower the $28,000 ...
Pricing issues have taken precedence as CVS Health’s (NYSE:CVS) pharmacy benefit manager, CVS Caremark, continues to hold off ...
Doctors at DAP Health have begun administering a new twice-a-year injectable HIV prevention medication, which was approved by the Food and Drug Administration in June. Gilead's drug lenacapavir ...
Despite highly effective HIV prevention drugs on the market, only a fraction of those at risk in the U.S. are taking them — or even know they're an option. It's called pre-exposure prophylaxis, or ...
A newly approved HIV medication provides near-total protection against infection with just two injections a year. It's called Lenacapavir. But the high price of the drug could limit its reach. A newly ...
Cabotegravir was already approved for use in England and Wales as part of a combination treatment for people living with HIV.
More than 40 years after the first AIDS cases, new long-acting drugs and antibody-based therapies are reviving hopes that HIV ...
A new analysis finds that generic lenacapavir, a twice-yearly HIV preventive treatment, could be mass produced for just $25 ...
With figures showing heterosexuals to be most at risk of contracting the virus, Anne Aslett says it’s time ‘pre-exposure’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback